Stocks and Investing Stocks and Investing
Wed, August 17, 2022

Derek Archila Maintained (BPMC) at Sell with Increased Target to $41 on, Aug 17th, 2022


Published on 2024-10-27 22:41:49 - WOPRAI, Derek Archila
  Print publication without navigation


Derek Archila of Wells Fargo, Maintained "Blueprint Medicines Corporation" (BPMC) at Sell with Increased Target from $40 to $41 on, Aug 17th, 2022.

Derek has made no other calls on BPMC in the last 4 months.



There are 8 other peers that have a rating on BPMC. Out of the 8 peers that are also analyzing BPMC, 3 agree with Derek's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Andrew Berens of "SVB Leerink" Maintained at Hold with Increased Target to $65 on, Wednesday, August 3rd, 2022
  • Michael Ulz of "Morgan Stanley" Maintained at Hold with Decreased Target to $65 on, Tuesday, June 14th, 2022
  • Christopher Raymond of "Piper Sandler" Maintained at Hold with Decreased Target to $65 on, Thursday, May 19th, 2022


These are the ratings of the 5 analyists that currently disagree with Derek


  • Dane Leone of "Raymond James" Maintained at Strong Buy with Decreased Target to $115 on, Wednesday, August 3rd, 2022
  • Terence Flynn of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $143 on, Wednesday, August 3rd, 2022
  • Matthew Biegler of "Oppenheimer" Initiated at Buy and Held Target at $80 on, Friday, July 8th, 2022
  • David Lebowitz of "Citigroup" Downgraded from Hold to Strong Sell and Decreased Target to $41 on, Friday, June 10th, 2022
  • Eun Yang of "Jefferies" Upgraded from Hold to Strong Buy and Decreased Target to $78 on, Wednesday, June 1st, 2022
Contributing Sources